A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01 (D7080C00001) study was based on strategic company portfolio prioritization.

Conditions

Advanced Solid Tumours
Non-Small Cell Lung Cancer (NSCLC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Colorectal Cancer (CRC)

Interventions

DRUG: AZD0022
DRUG: Cetuximab

Sponsor

AstraZeneca